New generation DES providing synergy of biodegradable polymer with microporous surface to enhance optimal performance



Less Polymeric Load Compared To Other DES

- One million pores per cm^2 with average depth of 2 µm ensures optimum drug release with minimal use of polymer
- Shellac Resin (Wax-Free) ensures better polymer- drug biding with negligible polymer flaking during stent expansion
- Drug and Polymer are co-released in 30 days

Better Endothelialisation & Superior Strut Coverage

- Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue
- No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis

translumina
LIMITLESS POSSIBILITIES

Yukon Choice Flex

Sirolimus Eluting Coronary Stent System

PRODUCT MATRIX / ORDERING INFORMATION*

Length (mm)	Diameter (mm)						
	2.00	2.25#	2.50	2.75	3.00	3.50	4.00
8.00	YCFX2008	YCFX2208	YCFX2508	YCFX 2708	YCFX 3008	YCFX3508	YCFX4008
12.00	YCFX2012	YCFX2212	YCFX2512	YCFX 2712	YCFX 3012	YCFX3512	YCFX4012
16.00	YCFX2016	YCFX2216	YCFX2516	YCFX 2716	YCFX 3016	YCFX3516	YCFX4016
18.00	YCFX2018	YCFX2218	YCFX2518	YCFX 2718	YCFX 3018	YCFX3518	YCFX4018
21.00	YCFX2021	YCFX2221	YCFX2521	YCFX 2721	YCFX 3021	YCFX3521	YCFX4021
24.00	YCFX2024	YCFX2224	YCFX2524	YCFX 2724	YCFX 3024	YCFX3524	YCFX4024
28.00	YCFX2028	YCFX2228	YCFX2528	YCFX 2728	YCFX 3028	YCFX3528	YCFX4028
32.00	YCFX2032	YCFX2232	YCFX2532	YCFX 2732	YCFX 3032	YCFX3532	YCFX4032
36.00#	-	-	-	YCFX 2736	YCFX 3036	YCFX3536	YCFX4036
40.00	-	-	-	YCFX 2740	YCFX 3040	YCFX3540	YCFX4040
44.00#	-	-	-	YCFX 2744	YCFX 3044	YCFX3544	YCFX4044
48.00#	-	-	-	YCFX 2748	YCFX 3048	YCFX3548	YCFX4048

Please contact our customer care for available sizes

Sizes Not CE Approved

COMPLIANCE CHART

Balloon Ø [mm]	Inflation Pressure (bar/10^5 Pa)															
						NP Nominal Pressure					RBP Rated Burst Pressure					
	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
Ø 2.00	1.83	1.87	1.90	1.93	1.96	2.00	2.03	2.06	2.10	2.13	2.16	2.20	2.23	2.26	2.29	
Ø 2.25	2.08	2.11	2.14	2.18	2.21	2.25	2.28	2.31	2.35	2.38	2.42	2.45	2.48	2.52	2.55	
Ø 2.50	2.33	2.36	2.40	2.43	2.47	2.50	2.53	2.57	2.60	2.64	2.67	2.70	2.74	2.77	2.81	
Ø 2.75	2.58	2.61	2.65	2.68	2.71	2.75	2.78	2.81	2.85	2.88	2.91	2.94	2.98	3.01	3.04	
Ø 3.00	2.81	2.85	2.89	2.92	2.96	3.00	3.04	3.07	3.11	3.15	3.18	3.22	3.26	3.29	3.33	
Ø 3.50	3.29	3.34	3.38	3.42	3.46	3.50	3.55	3.59	3.63	3.67	3.71	3.76	3.80	3.84	3.88	
Ø 4.00	3.75	3.80	3.85	3.90	3.95	4.00	4.06	4.11	4.16	4.21	4.26	4.31	4.36	4.41	4.46	

TECHNICAL SPECIFICATIONS

Cobalt Chromium Alloy (L605)			
Crossing profile	0.035'' / 0.889 mm	Entry Profile	0.016'' / 0.406 mm
Strut Thickness	0.0027'' / 68µm (SV)	Proximal Shaft Diameter	1.9 F
	0.0031'' / 79µm (MV)	Distal Shaft Diameter	2.7 F
Balloon Marker Material	Platinum / Iridium	Recommended Guide Wire	0.014''
		Guiding Catheter	min. 5 F

CE 1434

Manufactured By:
Translumina Therapeutics LLP
Plot No. #12, Pharmacity, Selaqui, Dehradun 248011 (Uttarakhand) India
Manufacturing License No. MFG/MD/2019/000227

Registered Office:
Translumina Therapeutics LLP
Ground Floor, Metro Tower, LSC MOR Land, New Rajinder Nagar, New Delhi 110 060 - India

Under Technological Collaboration With:
Translumina GmbH
Neue Rottenburger Strasse 50, D-72379 Hechingen, Germany

EC REP

CMC Medical Devices & Drugs S.L.
C/HoracioLengo N° 18, CP 29006, Málaga - Spain. Tel: +34951214054

Email: mmateos@cmcmedicaldevices.com | web: www.cmcmedicaldevices.com

Customer Care No: **+ 91 11-2874 2874**
Email: **info@translumina.in**
Web: **www.translumina.in** for more details.

Please refer to the Instructions for Use supplied with these devices for indications, contraindications, Adverse Events, suggested procedures, warnings and precautions.

translumina
LIMITLESS POSSIBILITIES

Doc.Ref.No : YCPC.BC.04-23.Rev.00

GERMAN EXCELLENCE

translumina
LIMITLESS POSSIBILITIES

Yukon Choice Flex

Sirolimus Eluting Coronary Stent System

Finding ways to the true joys of life.

Yukon Choice Flex

Sirolimus Eluting Coronary Stent System

Advanced platform for redefining flexibility in tortuous anatomy

Ideal Flexible Approach

Yukon Choice Flex offers new generation delivery system with "Flexi" platform providing unmatched delivery in most tortuous vessels.

Enhanced Delivery System

The customized 2-Connector stent design of Yukon Choice Flex with thinner structural elements confirms for optimal deliverability.

Proprietary Hypotube

The new shaft design offers optimal force transfer with excellent push-ability and kink resistance allowing high manoeuvrability, justifying its use for the most tortuous vessels.



10 YEARS CLINICAL DATA OF EFFICACY & SAFETY

In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.



Primary End Point



Definite /Probable stent thrombosis

Comparison of clinical outcomes at 10 years in patients treated with new-generation BP-SES versus new-generation PP-EES versus early generation SES.

*As per Clinical data with SS stent using similar microporous surface and drug coating technology

translumina
LIMITLESS POSSIBILITIES

Unmatched Safety- In Complex Patients Subset

Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in **patients with diabetes:** a pooled analysis of individual patient data from 3 randomised trials

International Journal of CARDIOLOGY

At 4 years, Biodegradable Polymer DES Yukon showed significantly lower rates of Stent Thrombosis compared to Durable Polymer SES in patients with Diabetes Mellitus.



Secondary safety end point: definite or probable stent thrombosis

Long-term outcomes of biodegradable versus durable polymer drug-eluting stents **in patients with acute ST-segment elevation myocardial infarction:** a pooled analysis of individual patient data from three randomised trials

EuroIntervention

At 4 years, Biodegradable Polymer DES compared to Durable Polymer SES demonstrated improved overall clinical outcome, reduced need for revascularisation as well as lower incidence of cardiac death or MI and reduced stent thrombosis in patients with STEMI.



Definite or probable stent thrombosis for the pooled population in each of the treatment groups. CI: confidence interval; HR: hazard ratio